Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged
NEW YORK, Aug. 25, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ: SYRS). Investors who purchased Syros securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SYRS.
Bronstein, Gewirtz & Grossman, LLC正在調查購買Syros Pharmaceuticals, Inc.（"Syros"或"the Company"）（納斯達克：SYRS）股票的潛在索賠。鼓勵購買Syros證券的投資者獲取更多信息並協助調查，請訪問該公司的網站：bgandg.com/SYRS。
Investigation Details
調查詳情
On August 12, 2024, Syros issued a press release "announcing that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial evaluating the triplet regimen of tamibarotene in combination with venetoclax and azacitidine compared to the doublet regimen of venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression." According to the Company, the "decision is based on the results of a prespecified interim analysis of the trial," and its analysis that "the probability for success . . . to demonstrate superiority at the final analysis . . . was considered low."
2024年8月12日，Syros發表新聞稿"宣佈將停止SELECt-AML-1第2期臨床試驗，評估tamibarotene與venetoclax和azacitidine三聯方案與venetoclax和azacitidine雙聯方案在新診斷、不適合的急性髓系白血病（AML）和RARA基因過度表達患者中的療效。"據公司稱，"此決定基於試驗的預先規定中期分析的結果"，並且其分析認爲"在最終分析中展示卓越性的成功概率考慮較低。"
What's Next?
下一步是什麼？
If you are aware of any facts relating to this investigation or purchased Syros securities, you can assist this investigation by visiting the firm's site: bgandg.com/SYRS. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
如果您了解與此調查相關的任何事實或購買了Syros證券，您可以通過訪問該公司的網站bgandg.com/SYRS來協助此調查。您還可以聯繫Bronstein，Gewirtz和Grossman，LLC的Peretz Bronstein或其客戶關係經理Nathan Miller：332-239-2660。
There is No Cost to You
您不需要支付任何費用
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
我們代表投資者進行集體訴訟，按照訴訟結果收取費用基礎。這意味着我們將要求法院償還我們的實際支出和律師費，通常是總賠償的一定比例，僅在我們成功時。
Why Bronstein, Gewirtz & Grossman
爲什麼選擇Bronstein，Gewirtz＆Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Bronstein，Gewirtz和Grossman，LLC是一家國際知名的公司，代表投資者進行證券欺詐集體訴訟和股東衍生訴訟。我們的公司已經爲全國投資者贏回了數億美元。
Attorney advertising. Prior results do not guarantee similar outcomes.
律師廣告。以前的結果不能保證相似的結果。
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]
聯繫人
Bronstein，Gewirtz＆Grossman，LLC
Peretz Bronstein或Nathan Miller
332-239-2660 | [email protected]
SOURCE Bronstein, Gewirtz & Grossman, LLC
資料來源：Bronstein，Gewirtz＆Grossman，LLC